Crescent Biopharma, Inc. Common Stock

Day range

$12.50 – $13.27

Open

$12.87

Prev close

$12.82

Volume

86.76K

Market cap

$476.22M

Shares out

37.14M

P/E

—

P/S

40.08

P/B

2.92

P/FCF

—

ROE

-89.4%

ROA

-79.9%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Partnership or collaborationOct 15, 2026

  In partnership with the Company, Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech"), is conducting the following clinical trials in China to evaluate CR-001 (also known as SKB118) in combination with sacituzumab tirumotecan ("sac-TMT"), a TROP2-directed ADC, with additional ADC combination studies planned.

• Public offeringJul 15, 2026

  On July 14, 2026, Crescent Biopharma, Inc. entered into an underwriting agreement relating to the issuance and sale in a public offering of (i) 8,094,793 of the Company's ordinary shares at an offering price to the public of $14.50 per Share, and (ii) pre-funded warrants to purchase an aggregate of 525,897 Ordinary Shares at a price to the public of $14.499 per pre-funded warrant.

• Preliminary resultsJul 14, 2026

  As of June 30, 2026, the Company estimates that its cash and cash equivalents were approximately $171.6 million. The cash and cash equivalents information above is based on preliminary unaudited information and management estimates for the quarter ended June 30, 2026, is not a comprehensive statement of our financial results as of and for the quarter ended June 30, 2026, and is subject to completion of the Company's financial closing procedures.

• Annual meeting resultsJun 3, 2026

  On June 2, 2026, Crescent Biopharma, Inc. (the "Company") held its annual general meeting of shareholders (the "Annual Meeting")... The following are the voting results for the proposals considered and voted upon at the Annual Meeting... each of Jonathan Violin, Ph.D. and Susan Moran, M.D., MSCE was elected as a Class II director, Proposal 2 and Proposal 3 were approved, and shareholders recommended a one year frequency for future advisory votes to approve named executive officer compensation.

• Private placementDec 4, 2025

  On December 4, 2025, the Company entered into a Securities Purchase Agreement (the 'Purchase Agreement') for a private placement (the 'Private Placement') with certain institutional and other accredited investors. Pursuant to the Purchase Agreement, the Purchasers agreed to purchase an aggregate of 13,795,685 ordinary shares at a purchase price per share of $13.41, for an aggregate purchase price of approximately $185.0 million.

Days to cover

6.8

Short interest

4.78M

Avg volume

697.4K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
  positiveGlobeNewswire Inc.· Jul 30, 2026
• Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
  positiveGlobeNewswire Inc.· Jul 14, 2026
• Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split
  GlobeNewswire Inc.· Oct 30, 2023
• Why Owens Corning Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
  Benzinga· Oct 25, 2023
• Why EngageSmart Shares Are Trading Higher By Around 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
  Benzinga· Oct 23, 2023